EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Medicaid expansion is associated with treatment receipt, timeliness, and outcomes among young adults with breast cancer

Xu Ji iD, Kewei Sylvia Shi, Kathryn J Ruddy, Jingxuan Zhao iD, Ann C Mertens iD, K Robin Yabroff, Sharon M Castellino, Xuesong Han iD

JNCI Cancer Spectrum · 31.08.2023 · 7 (5)

DOI: 10.1093/jncics/pkad067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 14.09.2023. Verfasst von Xu Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Medicaid, Breast Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Female breast cancer is a common cancer in young adults, an age group with the highest uninsured rate. Among 51 675 young adult women (ages 18-39 years) diagnosed with breast cancer between 2011 and 2018 in the National Cancer Database, we estimated changes in guideline-concordant treatment receipt, treatment timeliness, and survival associated with the Affordable Care Act Medicaid expansion. Of young adults with stage I-III estrogen receptor–positive or progesterone receptor–positive breast cancer, Medicaid expansion was associated with a net increase of 2.42 percentage points (95% confidence interval [CI] = 0.56 to 4.28 percentage points) in the percentage receiving endocrine therapy. Among all young adults with stage I-III breast cancer, Medicaid expansion was associated with a net reduction of 1.65 percentage points (95% CI = 0.08 to 3.22 percentage points) in treatment delays defined as treatment initiation of at least 60 days after diagnosis and a net increase of 1.00 percentage points (95% CI = 0.21 to 1.79 percentage points) in 2-year overall survival. Our study provides evidence of benefit in cancer care and outcomes from Medicaid expansion among the young adult population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicaidBreast NeoplasmsUnited StatesHumansFemaleYoung AdultPatient Protection and Affordable Care ActInsurance CoverageTime-to-Treatment

Autor:innen und Institutionen

  • Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
  • Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA.
  • Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Department of Epidemiology, Emory Rollins School of Public Health, Atlanta, GA, USA.

ORCID-Profile: Xu Ji, Jingxuan Zhao, Ann C Mertens, Xuesong Han

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health

Zitieren

APA

Ji, X., Shi, K. S., Ruddy, K. J., Zhao, J., Mertens, A. C., Yabroff, K. R., Castellino, S. M., & Han, X. (2023). Medicaid expansion is associated with treatment receipt, timeliness, and outcomes among young adults with breast cancer. JNCI Cancer Spectrum, 7(5). https://doi.org/10.1093/jncics/pkad067

Vancouver

Ji X, Shi KS, Ruddy KJ, Zhao J, Mertens AC, Yabroff KR, et al. Medicaid expansion is associated with treatment receipt, timeliness, and outcomes among young adults with breast cancer. JNCI Cancer Spectrum. 2023;7(5). doi:10.1093/jncics/pkad067

BibTeX
@article{Ji2023,
  author = {Ji, Xu and Shi, Kewei Sylvia and Ruddy, Kathryn J and Zhao, Jingxuan and Mertens, Ann C and Yabroff, K Robin and Castellino, Sharon M and Han, Xuesong},
  title = {Medicaid expansion is associated with treatment receipt, timeliness, and outcomes among young adults with breast cancer},
  journal = {JNCI Cancer Spectrum},
  year = {2023},
  volume = {7},
  number = {5},
  doi = {10.1093/jncics/pkad067}
}
Kostenlos starten →